HighTower Advisors’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$308K Sell
9,865
-164
-2% -$7.7K ﹤0.01% 3193
2026
Q2
$538K Buy
10,029
+409
+4% +$18.1K ﹤0.01% 2679
2026
Q1
$464K Buy
9,620
+300
+3% +$20.5K ﹤0.01% 2791
2025
Q4
$648K Buy
9,320
+320
+4% +$13.1K ﹤0.01% 2435
2025
Q3
$252K Buy
+9,000
New +$179K ﹤0.01% 3186

Other funds holding GPCR

HighTower Advisors's GPCR Position: Q3 2026 in Review

HighTower Advisors reduced its Structure Therapeutics (GPCR) stake by 1.6% in Q3 2026, selling an estimated $7.7K and leaving 9,865 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #3193.

HighTower Advisors first reported a position in GPCR in Q3 2025 and has held it in 5 quarters since. The position peaked at $648K in Q4 2025. 169 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • HighTower Advisors held 9,865 shares of Structure Therapeutics worth $308K as of Q3 2026.
  • HighTower Advisors sold 164 Structure Therapeutics shares in Q3 2026, an estimated $7.7K.
  • Structure Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3193 holding.
  • HighTower Advisors first reported a position in Structure Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • HighTower Advisors's Structure Therapeutics position peaked at $648K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.